Daffodil Centre, The University of Sydney, a Joint Venture with Cancer Council NSW, Sydney, Australia.
VCS Population Health, VCS Foundation, Melbourne, Australia.
Tumour Virus Res. 2021 Jun;11:200216. doi: 10.1016/j.tvr.2021.200216. Epub 2021 Apr 14.
Initially, three-dose schedules were recommended for vaccines against human papillomavirus (HPV); subsequently recommendations have been updated to a schedule of two doses delivered at least six (minimum five) months apart for those aged <15 years at dose 1. We aimed to re-estimate effective HPV vaccination coverage in Australia, considering reduced-dose schedules and possible one-dose effectiveness. We also aimed to identify which of the three school visits was most commonly missed amongst two-dose only recipients, to inform optimal timing of visits.
National vaccination register data were used to estimate: i) vaccination coverage at December 2017, either with a complete course (three or two sufficiently-spaced doses (>151 days apart)), or at least one dose; ii) for each birth cohort offered vaccination, the percentage of the initially targeted cohort with a complete course, or at least one dose (reflecting uptake at the time the vaccine was offered); and iii) among two-dose only recipients, the percentage who missed each of three school visits.
Including those with two sufficiently-spaced doses increased end-2017 coverage by 1.3-2.8% points in those vaccinated at school. Including those with at least one dose increased coverage further, by 6.5-9.5% points, mostly due to including those receiving multiple too-closely-spaced doses. One-dose coverage reached 90.9% and 86.9% in females and males respectively born in 2002. Among those vaccinated at school who received only two doses, it was much more common to miss the first (31.0% females; 32.5% males) or the third visit in the school year (54.6% females; 48.6% males) than the second (14.1% females; 18.8% males).
Including those with two sufficiently-spaced doses has a very modest impact on HPV vaccine coverage in Australia. If receiving at least one dose offers substantial protection, these data suggest that the school-based program is now achieving close to 90% coverage on this measure.
最初,人类乳头瘤病毒(HPV)疫苗推荐三剂接种方案;随后,对于 15 岁以下人群,首剂接种后至少 6 个月(至少 5 个月)推荐两剂方案。本研究旨在考虑减少剂量方案和可能的一剂有效性,重新估计澳大利亚 HPV 疫苗接种的有效性。我们还旨在确定两剂方案中哪些学校就诊最常被漏诊,以确定最佳就诊时间。
利用国家疫苗接种登记数据估计:i)2017 年 12 月,完全接种(三剂或两剂充分间隔(间隔 >151 天))或至少一剂的疫苗接种率;ii)对于每个接种疫苗的出生队列,完成初始目标人群接种的百分比,或至少一剂(反映疫苗接种时的接种率);iii)在仅接受两剂的人群中,错过三次学校就诊的百分比。
包括两剂充分间隔的接种者,使在校接种者的 2017 年底覆盖率增加了 1.3-2.8 个百分点。包括至少一剂接种者,覆盖率进一步增加了 6.5-9.5 个百分点,主要是因为包括了那些接受过多剂过近间隔接种的人群。2002 年出生的女性和男性分别有 90.9%和 86.9%达到一剂接种。在仅接受两剂接种的在校接种者中,错过第一年第一(31.0%女性;32.5%男性)或第三次就诊(54.6%女性;48.6%男性)的情况比错过第二次就诊(14.1%女性;18.8%男性)更为常见。
包括两剂充分间隔的接种者对澳大利亚 HPV 疫苗接种率的影响非常有限。如果至少一剂能提供实质性保护,这些数据表明,基于此措施,基于学校的方案现在已接近 90%的覆盖率。